drugset / Trial / NCT00993681

Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study

NCT00993681 ↗

Phase 3 Completed 2036 enrolled Intercell USA, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the efficacy of the Travelers' Diarrhea Vaccine System to actively immunize against Enterotoxigenic Escherichia coli disease in a field setting.

Timeline

Start
2009-10
Primary completion
2010-11
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator TD Vaccine System Vaccine 37.5 ug Other

Indications